Our latest news
What We’re Working On
Media Contact
Katie Engleman
katie@1abmedia.com
Bringing Meaningful Therapies from One to Many
-
May 8th, 2026
Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease Evidence Principles Process
Read More -
January 6th, 2026
Actio Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Read More -
December 5th, 2025
Actio Biosciences Announces Preclinical Data Highlighting Ability of ABS-1230 to Potently and Selectively Inhibit KCNT1 and Significantly Reduce Seizure Activity
Read More -
November 24th, 2025
Actio Biosciences to Present New Preclinical Data for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy, at the American Epilepsy Society Annual Meeting
Read More -
September 23rd, 2025
Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy
Read More